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 Market failure has meant that flucytosine, a potentially lifesaving medicine for the treatment of 
cryptococcal meningitis is not accessible in African treatment programmes 
 A recently established access programme has allowed for wide scale public sector access to 
flucytosine in South Africa 
 We advocate that access programmes for medicines be utilized more widely as part of the 
solution to addressing market failure  
 
Abstract 
Background 
Cryptococcal Meningitis (CM) is estimated to cause 181,000 deaths annually; with the majority 
occurring in Sub Saharan Africa. Flucytosine is recommended by the World Health Organization 
as part of the treatment for CM. Widespread use of flucytosine could reduce mortality in 
hospital by as much as 40% compared to the standard of care, yet due to market failure quality 
assured flucytosine remains unregistered and largely inaccessible throughout Africa. 
Methods 
The recently established South African flucytosine clinical access programme is an attempt to 
address market failure which led to a lack of public-sector access to flucytosine for cryptococcal 
meningitis, by making the medicine freely available to tertiary hospitals in South Africa. 
Results 
Between November 2018 and September 2019, 327 CM patients received flucytosine through 
this programme, with efforts to support sustainable national scale up presently ongoing. We 
describe why this programme was needed, its catalytic potential, what is still required to ensure 
widespread access to flucytosine, and observation from this experience that may have wider 
relevance. 
Conclusions 
The South African Flucytosine Access Programme illustrates how access programmes may be 
one part of the solution to addressing the vicious cycle of perceived low demand, limiting 
manufacturer interest in specific product markets. 
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The transition from phase 3 clinical trials demonstrating efficacy of a medicine to widespread 
access in routine-care settings can be slow and tortuous, particularly for neglected diseases 
such as cryptococcal meningitis (1). Here we outline the usefulness of clinical access 
programmes, one mechanism to bridge this period. The recently established South African 
flucytosine clinical access programme is an attempt to address market failure that led to a lack 
of public-sector access to flucytosine for cryptococcal meningitis. Initially, Médecins Sans 
Frontières (MSF) procured flucytosine with the support of South Africa’s National Department 
of Health, under an import exemption (in terms of Section 21 of the Medicines and Related 
Substances Act, 101 of 1965) in order to supply this unregistered medicine to tertiary public-
sector hospitals in the country. We describe why this programme was needed, its catalytic 
potential, what is still required to ensure widespread access to flucytosine, and observation 
from this experience that may have wider relevance. 
Flucytosine, in combination with amphotericin B, significantly reduces mortality among people 
living with human immunodeficiency virus (HIV) infection who suffer from cryptococcal 
meningitis, it has a favorable safety profile and allows for the duration of amphotericin B 
infusion to be decreased, thus reducing toxicity.(2) Quality assured flucytosine is however not 
registered in any country in Africa, the very place where it would be of most benefit (3). In sub-
Saharan Africa, this medicine is commonly substituted by fluconazole which is associated with 
inferior clinical outcomes (2). Those who do not tolerate amphotericin B may receive even less 
effective fluconazole monotherapy. Flucytosine, developed in 1957, has been off patent for 
decades, yet the cost in the US and other parts of the world has remained extraordinarily high 
because of manufacturer monopoly pricing (4), at around 25,000 US dollars per 2-week 
treatment course (Micromedex Redbook). Manufacturers seem to perceive the market for 
flucytosine elsewhere as unattractive while national departments of health have avoided its 
inclusion in guidelines and on essential medicines lists until registration is completed, the latter 
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a lengthy and complicated process in many countries. This has meant that most people with 
cryptococcal meningitis continue to receive sub-standard therapy or no therapy at all, hindering 
efforts to reduce the estimated 140,000 annual cryptococcal meningitis deaths in sub-Saharan 
Africa (5). 
Market failure with respect to flucytosine principally relates to issues at the following levels: i) 
At government level, this medicine appears to have been viewed as unaffordable (6). This may 
have been exacerbated by the fact that manufacturers have not always been transparent on 
pricing (author’s personal efforts to obtain pricing information) nor forthcoming with a reduced 
access price for the public sector (7). 
ii) On the manufacturer’s side, the profit margins from low- and middle-income countries 
(LMICs) may not be perceived as substantial enough to justify investing the time and resources 
needed to file for registration and scale up manufacturing and distribution. This is in contrast to 
the situation in North America, where the product is registered and available, albeit at a very 
high price.  
In addition, manufacturers have complained of poor demand, however this can only be 
generated if the product is registered and appears in guidelines in respective countries, a catch-
22 situation. 
iii) Providers are unfamiliar with the medicine so are less likely to seek to use it, even if 
available prior to registration off license. Flucytosine can be obtained in South Africa under the 
Section 21 exemption system.  
This has resulted in a vicious cycle where limited interest from end-users (clinicians treating 
people with HIV-associated cryptococcal meningitis) has led to weak and unarticulated 
demands from government, which in turn has contributed to the perception of the market as 
unattractive, thus severely limiting patient access (8). 
The publication of the Antifungal Combinations for Treatment of Cryptococcal Meningitis in 
Africa (ACTA) trial results (2)(9) has greatly strengthened calls to increase access to this 
medicine, with mortality reductions in the region of 40% reported at 10 weeks reported with 
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the use of flucytosine (versus fluconazole) in induction therapy in combination with 
amphotericin B for cryptococcal meningitis. The magnitude of benefit, and strength of evidence 
has helped to shift the argument for flucytosine access to a humanitarian, as well as a scientific 
imperative. 
The South African flucytosine clinical access programme was established in the second half of 
2018 by Médecins Sans Frontières (MSF) in conjunction with a range of key South African 
clinicians through the Southern African HIV Clinicians Society. It sought to ensure flucytosine 
supply to tertiary hospitals in South Africa, until such time as the medicine became available 
throughout the country.  This has contributed to some modest successes. Between 1st 
November 2018 and 1st September 2019, we have collected data on 327 patients treated 
within this programme. In-hospital mortality observed among cryptococcal meningitis patients 
treated during this period at supported sites was 25% during admission, compared to 36% 
mortality observed at the same sites prior to flucytosine introduction (10). While future more 
definitive comparisons will require adjustment for confounding; we provide this data to 
illustrate outcomes achievable with flucytosine in routine use. 
Along with this limited access, the South African National Essential Medicines List Adult Hospital 
Level Medication Review Process recently concluded that flucytosine should form part of the 
preferred regimen for cryptococcal meningitis treatment, “pending South African Health 
Products Regulatory Authority (SAHPRA) registration with a reduction in price” (11). 
The situation with regard to flucytosine access remains precarious. While industry interest in 
the medicine is increasing, the medicine remains unregistered and this modest programme 
established in South Africa appears to have exhausted all stock that the principal manufacturer 
(Mylan) states can be provided in the short term. This programme may be thought of as a 
transitional access mechanism, having the potential both to facilitate wider access (the 
humanitarian perspective) as well as to produce evidence of a market and of the medicine’s 
importance to public health. 
The role of civil society 
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There are currently many other medicines of public health importance in LMICs with good 
evidence of efficacy but poor accessibility.  These include directly acting antivirals (DAAs) for 
hepatitis C, delamanid for drug-resistant TB, and rifabutin for TB infection in patients with HIV. 
In the early era of the AIDS epidemic, the unacceptability of poor access to ART was prominent 
in the public discourse and led to vocal and effective civil society mobilization to demand fair 
access.  Around the turn of the century the treatment action campaign (TAC) and others 
mounted an effective “defiance campaign”, importing, alongside antiretrovirals, generic 
fluconazole at a time when price the registered originator version was a major impediment to 
accessing it for use in cryptococcal meningitis, with these efforts helping to catalyze wide 
systemic change (12). Such pressure would be useful now in the case of flucytosine and other 
essential but unavailable medicines, but is not currently seen in as vocal or impactful form. 
The role of donors 
We call upon funders to consider wider use of transitional access mechanisms such as clinical 
access programmes, given that they have the potential to provide data on the effectiveness and 
benefits of new regimens in real-world settings, establish the role of new medicines in high 
prevalence and resource-limited regions, create familiarity with use of the medicine among 
health care workers, and provide much needed access to patients while awaiting  registration 
and routine use. Such programmes also bring wider attention with the potential to promote 
meaningful dialogue between all vested stakeholders including civil society. 
Through these activities it may be possible to demonstrate the presence of a market to 
manufacturers, while supporting earlier registration by providing locally-derived data to 
relevant medicines regulators.  By institutionalizing the role of such programmes and 
mechanisms, expedited access to medicines of public health importance in LMIC settings can 
become the norm rather than the exception. However, this will require a willingness to think 
outside typical paradigms, where Non Governmental Organisations (NGOs) seek simply to help 
government reach predetermined objectives, and other stakeholders passively await the 
availability of new medicines. Donors should recognize and maximally leverage their relative 
flexibility in this arena. 
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Potential pitfalls 
We see such initiatives as distinct from manufacturer-sponsored and/or led donation 
programmes. Such programmes should be careful to balance the benefit to public health 
against the potential to distort or hinder market growth and in so doing, hampering longer-
term access. 
Access programmes should not be viewed as an alternative to, but rather as leading to, the 
ultimate aim of sustainable widespread public-sector access to medicines that have received 
regulatory approval and whose use will ultimately be integrated into routine programmes 
funded by national departments of health. Ensuring this transition necessitates close 
collaboration throughout with departments of health throughout the process. 
While such programmes may appear “light” in comparison to a trial, they do require careful 
coordination around the logistics of supply, pharmacovigilance reporting and follow up with 
implementing sites; practical support from an organization with an implementation presence, 
such MSF, may be useful in this regard. 
Summary 
The South African flucytosine access programme illustrates how access programmes may be 
one part of the solution to addressing the vicious cycle of perceived low demand, limiting 
manufacturer interest in specific product markets. 
In the case of flucytosine, there remains an urgent need for generic manufacturers to file for 
registration and for the medicine to be included in national level guidelines, which will facilitate 
its use in the countries where it will have the most public health impact. This requires 
continued sustained work from governments, civil society and other non-governmental actors. 
UNITAID will provide funds through a Clinton Health Access Initiative (CHAI) grant to ensure the 
continuation of the South African flucytosine clinical access programme. We hope that this will 
help encourage additional future investment in programmes to address market failure for key 
commodities needed in LMICs. We hope this experience will help such mechanisms to be more 
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widely acknowledged as having a legitimate space in the medicine development and access 
continuum, particularly where the human costs of delayed access are so high. 
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